C3a Human
Human Plasma.
Complement C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, C3, CPAMD1.
Sterile Filtered solution.
Greater than 98.0% as determined by SDS-PAGE.
Description
Human Complement C3a produced in Human plasma is an non glycosylated polypeptide chain containing 77 amino acids having a molecular weight of 9,089 daltons.
Product Specs
Human C3a, a component of the complement system, is generated through the enzymatic cleavage of C3 protein by C3 convertase. As an anaphylatoxin, C3a plays a role in inflammatory responses, including smooth muscle contraction, increased vascular permeability, vasodilation, and histamine release from mast cells and basophils. Unlike C5a, C3a does not significantly stimulate neutrophils or induce chemotaxis, granule release, or superoxide production. Its effects are mediated through the C3a Receptor, a G-protein coupled receptor primarily found on peripheral tissues, lymphoid cells, and in the central nervous system. The activity of C3a is regulated by the removal of its C-terminal arginine, a process rapidly facilitated by carboxypeptidase N in plasma.
Human Complement C3a, derived from human plasma, is a polypeptide chain comprising 77 amino acids. This non-glycosylated protein has a molecular weight of 9,089 daltons.
This product is provided as a sterile, filtered solution.
The C3a solution is prepared in phosphate-buffered saline (PBS) with a pH of 7.2.
For optimal stability, store Human C3a at 4°C. If used within 2-4 weeks, the entire vial can be stored at this temperature. For extended storage, freeze the product below -20°C. The addition of a carrier protein such as HSA or BSA (0.1%) is recommended for long-term storage. To maintain product integrity, avoid repeated freezing and thawing.
The purity of this product is greater than 98.0%, as determined by SDS-PAGE analysis.
Each plasma donation used in the production of this product has undergone rigorous testing and been found negative for antibodies to HIV-1, HIV-2, HCV, HTLV-I & II, and HBsAg. This ensures the safety and integrity of the product.
Complement C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, C3, CPAMD1.
Human Plasma.
Product Science Overview
Complement C3a is a crucial protein fragment in the human immune system, playing a significant role in the complement system. The complement system is a part of the innate immune response, which helps to clear pathogens from an organism. C3a is derived from the cleavage of complement component 3 (C3), one of the most abundant and central proteins in the complement system .
C3a is a 77-residue anaphylatoxin, a type of protein that can cause rapid degranulation of mast cells, leading to inflammation . It is formed when C3 is cleaved by C3-convertase into C3a and C3b. This cleavage occurs through three pathways: the classical pathway, the lectin pathway, and the alternative pathway . The classical pathway is initiated by antibodies bound to pathogens, the lectin pathway by pattern-recognition receptors binding to pathogen-associated molecular patterns, and the alternative pathway is constantly active and can be triggered by pathogen surfaces .
C3a plays a multifaceted role in the immune response. It binds to the C3a receptor (C3aR), a G protein-coupled receptor, to induce various immune responses . These responses include:
- T cell activation and survival: C3a helps in the activation and survival of T cells, which are essential for adaptive immunity .
- Angiogenesis stimulation: It promotes the formation of new blood vessels .
- Chemotaxis: C3a attracts immune cells to the site of infection .
- Mast cell degranulation: It causes mast cells to release histamine and other chemicals, leading to inflammation .
- Macrophage activation: C3a activates macrophages, which are crucial for phagocytosis and pathogen clearance .
C3a has both pro-inflammatory and anti-inflammatory effects, making it a critical component in maintaining immune balance . Its dysregulation can lead to various immune disorders. For instance, excessive C3a activity can contribute to chronic inflammatory diseases, while insufficient activity can result in increased susceptibility to infections .
Recent research has shown that C3a has potential therapeutic applications. For example, studies in mice have demonstrated that C3a can be an effective treatment after a stroke, leading to further investigations into its potential use in humans . Additionally, understanding the role of C3a in immune responses can help develop new treatments for immune-related diseases.
